Bristol-Myers Squibb Co vs SkyWest Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.71 (market cap $129.94B), while SkyWest Inc trades at $107.48 (market cap $4.19B). The key difference: Bristol-Myers Squibb Co is far larger — about 31× SkyWest Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| BMY | SKYW | |
|---|---|---|
Market Cap | $129.94B | $4.19B |
Sector | Health | Technology |
52-Week High | $65.89 | $123.72 |
52-Week Low | $42.60 | $78.40 |
Enterprise Value | $163.92B | $5.97B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SkyWest (SKYW) trades at $106.38, down 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $109.33. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales alongside institutional interest and a 7.7% post-earnings rally noted by Zacks Investment Research on 2026-07-27.
The outlook is cautiously positive given analyst buy ratings (56.25%) and undervalued metrics, but risks include fuel cost volatility from Iran war impacts (New York Post, 2026-07-07) and mixed earnings performance. Upside potential exists if Q3 2026 meets its $3.13 EPS expectation, balancing insider selling with buyback support.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →